(Reuters) – Amgen said on Wednesday it does not see any bone safety concerns around the use of its experimental obesity drug, a day after data from an early-stage study dragged its stock 7% lower.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
Comments